Subscribe to Newsletter

Standards & Regulation

Business & Regulation Standards & Regulation

FDA Warning Letters: September 2024 Edition

| Stephanie Vine | 3 min read

Here’s a look at recent violations cited in FDA Warning Letters: fly pupae, cross contamination, trial dosing errors, and more.

Business & Regulation Business Practice

Driving the Future of Biopharma

| Rob Coker

Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review.

Business & Regulation Standards & Regulation

AstraZeneca Flu Vaccine Approved For Self-Administration

| Rob Coker

AstraZeneca’s FluMist is the first flu vaccine to be approved for self-administration.

Business & Regulation Standards & Regulation

The Demands and Ethical Obligations of the DSCSA

| Matt Sample, Gregg Gorniak | 3 min read

The deadline for the US Drug Supply Chain Security Act is approaching.

Business & Regulation Supply Chain

Where Have All the Drugs Gone?

| 6 min read

Drug shortages are everywhere. We speak with Vimala Raghavendran at the US Pharmacopeia to get the full picture.

Business & Regulation Business Practice

Why Pharma Must Embrace AI and Open Source

| Brendan Frey | 4 min read

With open minds and open sources, the future is foundational – and bright.

Business & Regulation Standards & Regulation

EMA: No to Lecanemab

| Stephanie Vine | 3 min read

Lecanemab is refused marketing authorization by the European Medicines Agency.

Business & Regulation Standards & Regulation

The Choice: To Be Cured or to Have Children?

| Stephanie Vine

Fertility support programs for gene therapy Medicare patients are being blocked in the US.

Business & Regulation Standards & Regulation

Starting with the End in Mind

| Drew Hope | 7 min read

Collaboration and thoughtful automation at scale will be critical for unlocking cell and gene therapies for patients

Business & Regulation Supply Chain

Political Change Around China Means Change for Pharma

| Kerry Pickstone | 4 min read

Why companies must tighten their supply chains in light of Chinese anti-espionage laws and other regulatory clampdowns.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register